WOSCOPS

	Low Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low LDL High LDL
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Prognosis and Complications
Diagnosis
Laboratory Findings
Treatment
Medical Therapy
Landmark Trials
Future or Investigational Therapies
Case Studies
Case #1
WOSCOPS On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of WOSCOPS All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on WOSCOPS
CDC on WOSCOPS
WOSCOPS in the news
Blogs on WOSCOPS
Directions to Hospitals Treating Low density lipoprotein
Risk calculators and risk factors for WOSCOPS

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for WOSCOPS.

Overview

Treatment with pravastatin 40 mg daily in 6595 men with hypercholesterolemia resulted in a significant reduction in the incidence of fatal and non-fatal myocardial infarction and death from cardiovascular causes, without a difference in the deaths due to non-cardiovascular causes in a follow-up period of 4.9 years^[1].

References

↑ Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW; et al. (1995). "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group". N Engl J Med. 333 (20): 1301–7. doi:10.1056/NEJM199511163332001. PMID 7566020.

[pmid7566020-1] Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW; et al. (1995). "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group". N Engl J Med. 333 (20): 1301–7. doi:10.1056/NEJM199511163332001. PMID 7566020.

[1]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

WOSCOPS

Overview

References

Navigation menu